← Back to Search

Other

CYR-064 dose 2 for Reduced Sense of Smell

Verified Trial
Phase 2
Recruiting
Led By Mas Takashima, MD
Research Sponsored by Cyrano Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male or female 18-65 years of age.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 32 weeks
Awards & highlights

Study Summary

This trial is testing the safety and effectiveness of a drug called CYR-064. It will be a fair and unbiased study, with some participants receiving the actual drug and others receiving a placebo. The

Who is the study for?
This trial is for men and women aged 18-65 who've lost their sense of smell but don't have any nasal blockages or diseases causing it. They must be able to take the study drug themselves and follow the trial's procedures.Check my eligibility
What is being tested?
The trial tests CYR-064 against a placebo to see if it's safe and works for people with reduced sense of smell. Participants are randomly chosen to receive either CYR-064 or a fake drug, without knowing which one they get.See study design
What are the potential side effects?
Since this summary doesn't provide specific side effects of CYR-064, we can say that potential side effects will be monitored throughout the study as part of assessing the safety of the treatment.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 65 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 32 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 32 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
- Safety and Tolerability
Secondary outcome measures
Change in Visual Rating Scale (VRS) scores
Mean Change in NRS-11 Smell-PRO
Mean Change in NRS-11 Taste-PRO
+2 more

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: CYR-064 dose 2Experimental Treatment1 Intervention
Treatment with nasal solution of CYR-064 twice a day for 24 weeks. CYR-064 will be self-administered by patients.
Group II: CYR-064 dose 1Active Control1 Intervention
Treatment with nasal solution of CYR-064 twice a day for 24 weeks. CYR-064 will be self-administered by patients.
Group III: PlaceboPlacebo Group1 Intervention
Treatment with Placebo nasal solution for 24 weeks. CYR-064 will be self-administered by patients.

Find a Location

Who is running the clinical trial?

Cyrano Therapeutics, Inc.Lead Sponsor
Mas Takashima, MDPrincipal InvestigatorThe Methodist Hospital Research Institute
1 Previous Clinical Trials
116 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current number of individuals actively participating in this clinical trial?

"Indeed, the information provided on clinicaltrials.gov indicates that this particular clinical trial is actively seeking eligible participants. The initial posting of the trial was made on September 26th, 2023 and it was last updated on December 14th, 2023. This study aims to recruit a total of 150 individuals from one designated location."

Answered by AI

Are individuals currently able to apply and participate in this ongoing clinical trial?

"Indeed, the details provided on clinicaltrials.gov indicate that this particular clinical trial is actively seeking suitable candidates. The initial posting of the trial was recorded on September 26th, 2023 and it underwent its most recent revision on December 14th, 2023. This study aims to recruit a total of 150 patients from a single designated site."

Answered by AI

Is the inclusion criteria for this research study limited to individuals who are above 30 years old?

"To be eligible for this clinical trial, participants must fall between the age range of 18 and 65. For individuals under the age of 18, there is only one available trial option. Conversely, there are ten trials specifically designed for patients over the age of 65."

Answered by AI

What is the level of risk associated with administering CYR-064 dose 2 to individuals?

"Based on our assessment at Power, the safety rating for dose 2 of CYR-064 in this Phase 2 trial is a 2. This indicates that there is preliminary data supporting its safety but no evidence yet regarding efficacy."

Answered by AI

Who else is applying?

What site did they apply to?
Tandem Clinical Research, Marrero
Tandem Clinical Research - Houma, LA
What portion of applicants met pre-screening criteria?
Met criteria

How responsive is this trial?

Typically responds via
Phone Call
Most responsive sites:
  1. Tandem Clinical Research - Houma, LA: < 48 hours
Average response time
  • < 2 Days
Recent research and studies
clinicaltrials.govStudy
Study of CYR-064 Versus Placebo in Patients.
2023. "Study of CYR-064 Versus Placebo in Patients.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06019000.
All > Tandem > Anosmia
~62 spots leftby Sep 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top